Skip to main content

Barclays Keeps Their Buy Rating on Omada Health, Inc. (OMDA)

Tipranks - Tipranks - Wed Jan 14, 4:00AM CST

In a report released today, Saket Kalia from Barclays maintained a Buy rating on Omada Health, Inc., with a price target of $22.00.

Claim 70% Off TipRanks Premium

According to TipRanks, Kalia is a 5-star analyst with an average return of 8.3% and a 55.60% success rate. Kalia covers the Technology sector, focusing on stocks such as Check Point, Varonis Systems, and Tenable Holdings.

In addition to Barclays, Omada Health, Inc. also received a Buy from Morgan Stanley’s Craig Hettenbach in a report issued yesterday. However, on January 9, Wells Fargo initiated coverage with a Hold rating on Omada Health, Inc. (NASDAQ: OMDA).

See Insiders’ Hot Stocks on TipRanks >>

Based on Omada Health, Inc.’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $68.03 million and a GAAP net loss of $3.18 million. In comparison, last year the company earned a revenue of $35.1 million and had a GAAP net loss of $18.97 million

Read More on OMDA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).